Exor: Fiat Crisis to Ferrari Glory - [Business Breakdowns, EP.229]

October 1, 2025

48 min episode · 2 min read

Krishna Mohanaj

Episode

48 min

Read time

2 min

AI-Generated Summary

Published Jan 2, 2026

Key Takeaways

✓Ferrari value unlock: Exor sold €3 billion of Ferrari shares in February when the stake reached 50% of portfolio value, redeploying proceeds into share buybacks at 50-60% NAV discount and new investments in healthcare technology.
✓Decisive capital allocation: The company refreshes its asset mix two to three times annually, maintaining 20% debt-to-assets maximum while focusing on three sectors: healthcare technology, luxury goods, and artificial intelligence through strategic partnerships and board positions.
✓Healthcare strategy execution: Philips stake increased to 20% with board presence, combined with Institute BioMeru investment, positions Exor as legitimate health tech player. The sector offers secular growth in imaging, diagnostics, genomics, and medical services with patient capital advantage.
✓NAV growth measurement: Management benchmarks performance against MSCI World index using NAV per share growth as primary metric. Past performance driven entirely by Ferrari appreciation, while Stellantis, CNH, and Philips trade at undemanding multiples during cyclical troughs.

What It Covers

Exor operates as a Dutch holding company controlled by the Agnelli family, managing €45 billion across Ferrari, Stellantis, CNH, and Philips. The company trades at 50-60% discount to NAV despite systematic portfolio transformation.

Key Questions Answered

•Ferrari value unlock: Exor sold €3 billion of Ferrari shares in February when the stake reached 50% of portfolio value, redeploying proceeds into share buybacks at 50-60% NAV discount and new investments in healthcare technology.
•Decisive capital allocation: The company refreshes its asset mix two to three times annually, maintaining 20% debt-to-assets maximum while focusing on three sectors: healthcare technology, luxury goods, and artificial intelligence through strategic partnerships and board positions.
•Healthcare strategy execution: Philips stake increased to 20% with board presence, combined with Institute BioMeru investment, positions Exor as legitimate health tech player. The sector offers secular growth in imaging, diagnostics, genomics, and medical services with patient capital advantage.
•NAV growth measurement: Management benchmarks performance against MSCI World index using NAV per share growth as primary metric. Past performance driven entirely by Ferrari appreciation, while Stellantis, CNH, and Philips trade at undemanding multiples during cyclical troughs.

Notable Moment

At age 27, John Elkan inherited a failing Fiat facing bankruptcy with four CEOs in three years. His controversial decision to hire outsider Sergio Marchionne, who extracted $2 billion from General Motors, transformed the company from crisis to Chrysler merger.

Know someone who'd find this useful?